This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Global Survey Reveals More Than A Quarter Of Canadians With Type 2 Diabetes Do Not Take Insulin As Prescribed And One Third Are Experiencing Events Of Low Blood Sugar Frequently

About Novo Nordisk Canada Inc.

Novo Nordisk is a healthcare company and a world leader in diabetes care and biopharmaceuticals.  Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society.  Novo Nordisk's business is driven by the Triple Bottom Line:  a commitment to economic success, environmental soundness, and social responsibility to employees and customers. For more information, visit www.novonordisk.ca.



i "Leading the Fight", Canadian Diabetes Association, accessed August 11, 2011, http://www.diabetes.ca/about-us/leading-the-fight/ ii "Diabetes in Canada: Facts and figures from a public health perspective", Public Health Agency of Canada. Accessed September 7, 2012 at http://www.phac-aspc.gc.ca/cd-mc/publications/diabetes-diabete/facts-figures-faits-chiffres-2011/chap5-eng.php iii "Signs and Symptoms of Hypoglycemia", Canadian Diabetes Association. Accessed September 7, 2012 at http://www.diabetes.ca/Files/kwd_signs.pdf iv Bunitz, Daniel et al. "Emergency Hospitalizations for Adverse Drug Events in Older Americans", NEJM 2011; 365:2002-12. v Canadian Diabetes association. Hypoglycemia: Low Blood Glucose. Accessed September 12, 2012 at http://www.diabetes.ca/files/for-professionals/hypoglycemia-tool-kidney-disease.pdf



SOURCE Novo Nordisk Canada Inc.

Video with caption: "Video: Canadians with type 2 diabetes are not taking insulin as prescribed to reduce the risk of experiencing low blood sugar at night.". Video available at: http://stream1.newswire.ca/cgi-bin/playback.cgi?file=20121128_C3967_VIDEO_EN_21297.mp4&posterurl=http://photos.newswire.ca/images/20121128_C3967_PHOTO_EN_21297.jpg&clientName=Novo%20Nordisk%20Canada%20Inc%2E&caption=Video%3A%20Canadians%20with%20type%202%20diabetes%20are%20not%20taking%20insulin%20as%20prescribed%20to%20reduce%20the%20risk%20of%20experiencing%20low%20blood%20sugar%20at%20night%2E&title=NOVO%20NORDISK%20CANADA%20INC%2E%20%2D%20Global%20survey%20reveals%20more%20than%20a%20quarter%20of%20Canadians%20with%20type%202%20diabetes%20do%20not%20take%20insulin%20as%20prescribed%20and%20one%20third%20are%20experiencing%20events%20of%20low%20blood%20sugar%20frequently&headline=Global%20survey%20reveals%20more%20than%20a%20quarter%20of%20Canadians%20with%20type%202%20diabetes%20do%20not%20take%20insulin%20as%20prescribed%20and%20one%20third%20are%20experiencing%20events%20of%20low%20blood%20sugar%20frequently

Audio with caption: "Audio: One in five Canadian patients deliberately do not take insulin as prescribed to reduce the risk of experiencing low blood sugar at night". Audio available at: http://stream1.newswire.ca/media/2012/11/28/20121128_C3967_AUDIO_EN_21299.mp3

PDF available at: http://stream1.newswire.ca/media/2012/11/28/20121128_C3967_DOC_EN_21292.pdf

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
4 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,279.74 +13.75 0.08%
S&P 500 2,010.40 -0.96 -0.05%
NASDAQ 4,579.7890 -13.6380 -0.30%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs